Last reviewed · How we verify
Rituximab and Hyaluronidase Human
Rituximab and Hyaluronidase Human is a Monoclonal antibody with recombinant human hyaluronidase Biologic drug developed by National Cancer Institute (NCI). It is currently in Phase 3 development for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis. Also known as: Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human.
Rituximab targets CD20 on B cells to deplete them, while hyaluronidase enables subcutaneous delivery by breaking down hyaluronic acid in subcutaneous tissue.
Rituximab targets CD20 on B cells to deplete them, while hyaluronidase enables subcutaneous delivery by breaking down hyaluronic acid in subcutaneous tissue. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis.
At a glance
| Generic name | Rituximab and Hyaluronidase Human |
|---|---|
| Also known as | Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Rituxan Hycela, |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | Monoclonal antibody with recombinant human hyaluronidase |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab is a chimeric monoclonal antibody that binds CD20 antigen on B lymphocytes, leading to B-cell depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. The addition of human hyaluronidase allows for subcutaneous administration instead of intravenous infusion, improving patient convenience and potentially reducing infusion-related reactions.
Approved indications
- B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
Common side effects
- Infusion-related reactions
- Infection
- Cytopenias
- Fatigue
- Injection site reactions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (PHASE3)
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission (PHASE3)
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (PHASE3)
- Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas (PHASE2)
- A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (PHASE2)
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab and Hyaluronidase Human CI brief — competitive landscape report
- Rituximab and Hyaluronidase Human updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about Rituximab and Hyaluronidase Human
What is Rituximab and Hyaluronidase Human?
How does Rituximab and Hyaluronidase Human work?
What is Rituximab and Hyaluronidase Human used for?
Who makes Rituximab and Hyaluronidase Human?
Is Rituximab and Hyaluronidase Human also known as anything else?
What drug class is Rituximab and Hyaluronidase Human in?
What development phase is Rituximab and Hyaluronidase Human in?
What are the side effects of Rituximab and Hyaluronidase Human?
What does Rituximab and Hyaluronidase Human target?
Related
- Drug class: All Monoclonal antibody with recombinant human hyaluronidase drugs
- Target: All drugs targeting CD20
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Oncology, Immunology
- Indication: Drugs for B-cell non-Hodgkin lymphoma
- Indication: Drugs for Chronic lymphocytic leukemia
- Indication: Drugs for Rheumatoid arthritis
- Also known as: Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Rituxan Hycela,
- Compare: Rituximab and Hyaluronidase Human vs similar drugs
- Pricing: Rituximab and Hyaluronidase Human cost, discount & access